• A-769662: Applied Workflows for Precise AMPK Activation in M

  2026-04-28

  A-769662 delivers robust, reversible activation of AMPK, enabling researchers to dissect energy metabolism and fatty acid synthesis with high specificity. Its dual action on both AMPK signaling and proteasome function, coupled with predictable in vitro and in vivo profiles, makes it a benchmark tool for metabolic disease and autophagy research.

• PF-562271 HCl: Applied FAK/Pyk2 Inhibition in Cancer Researc

  2026-04-28

  PF-562271 HCl enables precise, reversible inhibition of FAK/Pyk2 signaling, empowering cancer researchers to dissect tumor growth and metastasis mechanisms. This guide delivers proven workflows, troubleshooting strategies, and expert-backed protocol enhancements to maximize reproducibility and insight in preclinical oncology.

• Ouabain (SKU B2270): Reliable Na⁺/K⁺-ATPase Inhibition for L

  2026-04-27

  This article addresses practical challenges in cell viability and cardiovascular research, demonstrating how Ouabain (SKU B2270) enables reproducible Na⁺/K⁺-ATPase inhibition. Grounded in literature and protocol data, it guides researchers toward robust experimental design and data interpretation using APExBIO's Ouabain.

• BMS 309403: FABP4 Inhibitor Workflows for Atherosclerosis Re

  2026-04-27

  BMS 309403 offers precision inhibition of FABP4, unlocking advanced experimental workflows for dissecting lipid metabolism and inflammation in cardiovascular disease models. Discover protocol-driven strategies, troubleshooting insights, and the translational impact of targeting FABP4 with this potent tool compound.

• Thrombin B Chain Fragment: Beyond Coagulation to Disease Mod

  2026-04-26

  Explore the advanced roles of thrombin, a trypsin-like serine protease, in coagulation and vascular pathology. This article uniquely bridges mechanistic insights with translational applications, empowering researchers to leverage high-purity Coagulation Factor II (Thrombin) B Chain Fragment [Homo sapiens] for next-generation disease modeling.

• Activity-Driven LGI1 Surface Dynamics Regulate Synaptic Func

  2026-04-25

  Cuhadar et al. (2024) reveal that neuronal activity dynamically controls the abundance of LGI1 at the presynaptic surface, thereby modulating excitatory neurotransmission. This work clarifies the mechanistic basis for LGI1’s role in glutamatergic signaling and provides direct evidence linking surface LGI1 remodeling to synaptic strength and disease.

• Direct Mouse Genotyping Kit: Streamlined PCR from Mouse Tiss

  2026-04-24

  Unlock high-throughput, purification-free mouse genotyping with the Direct Mouse Genotyping Kit, designed for robust PCR directly from tissue lysates. This kit accelerates genetic screening in biomedical research and offers actionable troubleshooting for reproducible results.

• YTHDF1 Phase Separation Controls SSC Fate via IkB-NF-kB-CCND

  2026-04-24

  This study demonstrates that YTHDF1-mediated liquid-liquid phase separation (LLPS) is essential for the transdifferentiation of spermatogonial stem cells (SSCs) to neural stem cell-like cells, primarily by modulating the IkB-NF-kB-CCND1 signaling axis. The findings provide a mechanistic link between RNA methylation, protein-RNA condensates, and cell fate decisions, highlighting new opportunities for translational research in developmental and neurological biology.

• Tau Ser356 Phosphorylation in Alzheimer’s: NUAK Inhibition I

  2026-04-23

  Taylor et al. (2023) identify tau phosphorylated at serine 356 (p-tau Ser356) as a Braak stage-dependent marker closely associated with Alzheimer’s disease pathology. Their study demonstrates that pharmacological NUAK1 inhibition selectively reduces p-tau Ser356 in both mouse and human brain tissues, informing future strategies for tau-targeted therapeutics.

• Flumequine: High-Purity DNA Topoisomerase II Inhibitor for R

  2026-04-23

  Flumequine is a potent DNA topoisomerase II inhibitor with an IC50 of ~15 μM. Its defined purity and solubility profile make it ideal for DNA replication research and topoisomerase II inhibition assays. The compound’s stability and performance have been validated in both product and peer-reviewed sources.

• Rifampin Applications: Superior Transcription Inhibition in

  2026-04-22

  Rifampin, a leading rifamycin antibiotic from APExBIO, enables precise, reproducible transcriptional inhibition for bacterial resistance mechanism research and synthetic biology. This article details workflow optimizations, practical troubleshooting, and protocol specifications that help scientists leverage Rifampin's unique properties for advanced experimental outcomes.

• PPM-18 for iNOS Inhibition: Workflows, Assay Design & NF-κB

  2026-04-22

  PPM-18 enables precise modulation of NF-κB and iNOS pathways for robust inflammation and sepsis research. This guide delivers data-driven workflows, troubleshooting tips, and direct translation of key literature to optimize your experimental outcomes.

• 12-O-tetradecanoyl Phorbol-13-acetate (TPA): Advanced Mechan

  2026-04-21

  Explore the latest scientific perspectives on 12-O-tetradecanoyl phorbol-13-acetate (TPA) as a precise tool for ERK/MAPK pathway activation. This article delivers deeper mechanistic analysis and unique assay guidance, setting it apart from conventional lab-focused TPA content.

• ATS-9R: Precision Gene Silencing in Adipocytes for Metabolic

  2026-04-21

  ATS-9R (Adipocyte-targeting sequence-9-arginine) delivers nucleic acids directly to white adipose tissue via Prohibitin-mediated endocytosis, enabling efficient gene silencing with minimal off-target effects. This guide details experimental workflows, application advantages, and troubleshooting strategies to maximize reproducibility in obesity and metabolic disease models.

• Entecavir (BMS200475): Potent Inhibitor of Hepatitis B Repli

  2026-04-20

  Entecavir is a selective hepatitis B virus (HBV) DNA polymerase inhibitor with robust efficacy in chronic HBV infection and a low resistance rate in treatment-naïve patients. Its validated clinical use extends to lamivudine-resistant and decompensated liver disease populations. This dossier synthesizes atomic, verifiable facts on its mechanism, benchmarks, and workflow integration.

15760 records 1/1051 page Next 12345 下5页 Last page